Mid-way through the 2020 Legislative Session there are a number of pharmacy-related bills still making their way through the process: House Bill 2251 extends the reporting requirement when dispensing biosimilars to 2025; Substitute House Bill 2438 imposes a 1 cent per MME on manufacturers if more than 100,000 MME’s are dispensed within a quarter; 2nd Substitute Senate Bill 5601 address health care benefit managers including PBM’s; Substitute Senate Bill 6086 addresses pharmacy remote dispensing; 2nd Substitute Senate Bill 6087 limits co-payments and cost-sharing to patients on insulin to $100 per month; and Substitute Senate Bill 6113 creates a central insulin purchasing program which includes among others an independent and a chain pharmacist on the work group.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.